JP2006516652A5 - - Google Patents

Download PDF

Info

Publication number
JP2006516652A5
JP2006516652A5 JP2006503317A JP2006503317A JP2006516652A5 JP 2006516652 A5 JP2006516652 A5 JP 2006516652A5 JP 2006503317 A JP2006503317 A JP 2006503317A JP 2006503317 A JP2006503317 A JP 2006503317A JP 2006516652 A5 JP2006516652 A5 JP 2006516652A5
Authority
JP
Japan
Prior art keywords
composition
peptide
amino acids
minimum
net positive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006503317A
Other languages
English (en)
Japanese (ja)
Other versions
JP4838114B2 (ja
JP2006516652A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/003193 external-priority patent/WO2004070054A2/en
Publication of JP2006516652A publication Critical patent/JP2006516652A/ja
Publication of JP2006516652A5 publication Critical patent/JP2006516652A5/ja
Application granted granted Critical
Publication of JP4838114B2 publication Critical patent/JP4838114B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2006503317A 2003-02-04 2004-02-03 ミトコンドリア透過性転移の阻止方法 Expired - Lifetime JP4838114B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US44477703P 2003-02-04 2003-02-04
US60/444,777 2003-02-04
US53569004P 2004-01-08 2004-01-08
US60/535,690 2004-01-08
PCT/US2004/003193 WO2004070054A2 (en) 2003-02-04 2004-02-03 Methods for preventing mitochondrial permeability transition

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010241738A Division JP5775285B2 (ja) 2003-02-04 2010-10-28 ミトコンドリア透過性転移の阻止方法

Publications (3)

Publication Number Publication Date
JP2006516652A JP2006516652A (ja) 2006-07-06
JP2006516652A5 true JP2006516652A5 (https=) 2007-10-18
JP4838114B2 JP4838114B2 (ja) 2011-12-14

Family

ID=32853391

Family Applications (7)

Application Number Title Priority Date Filing Date
JP2006503317A Expired - Lifetime JP4838114B2 (ja) 2003-02-04 2004-02-03 ミトコンドリア透過性転移の阻止方法
JP2010241738A Expired - Lifetime JP5775285B2 (ja) 2003-02-04 2010-10-28 ミトコンドリア透過性転移の阻止方法
JP2013182343A Expired - Lifetime JP5837542B2 (ja) 2003-02-04 2013-09-03 ミトコンドリア透過性転移の阻止方法
JP2014202889A Expired - Lifetime JP6126059B2 (ja) 2003-02-04 2014-10-01 ミトコンドリア透過性転移の阻止方法
JP2015135207A Expired - Lifetime JP6166312B2 (ja) 2003-02-04 2015-07-06 ミトコンドリア透過性転移の阻止方法
JP2017025764A Pending JP2017095519A (ja) 2003-02-04 2017-02-15 ミトコンドリア透過性転移の阻止方法
JP2019001256A Pending JP2019089773A (ja) 2003-02-04 2019-01-08 ミトコンドリア透過性転移の阻止方法

Family Applications After (6)

Application Number Title Priority Date Filing Date
JP2010241738A Expired - Lifetime JP5775285B2 (ja) 2003-02-04 2010-10-28 ミトコンドリア透過性転移の阻止方法
JP2013182343A Expired - Lifetime JP5837542B2 (ja) 2003-02-04 2013-09-03 ミトコンドリア透過性転移の阻止方法
JP2014202889A Expired - Lifetime JP6126059B2 (ja) 2003-02-04 2014-10-01 ミトコンドリア透過性転移の阻止方法
JP2015135207A Expired - Lifetime JP6166312B2 (ja) 2003-02-04 2015-07-06 ミトコンドリア透過性転移の阻止方法
JP2017025764A Pending JP2017095519A (ja) 2003-02-04 2017-02-15 ミトコンドリア透過性転移の阻止方法
JP2019001256A Pending JP2019089773A (ja) 2003-02-04 2019-01-08 ミトコンドリア透過性転移の阻止方法

Country Status (13)

Country Link
US (8) US7576061B2 (https=)
EP (9) EP3144009A1 (https=)
JP (7) JP4838114B2 (https=)
CN (3) CN104225574B (https=)
AU (1) AU2004209663B2 (https=)
CA (1) CA2515080C (https=)
CY (2) CY1114959T1 (https=)
DK (3) DK1599216T3 (https=)
ES (3) ES2605504T3 (https=)
HU (1) HUE027110T2 (https=)
PT (2) PT2656854E (https=)
SI (1) SI2656854T1 (https=)
WO (1) WO2004070054A2 (https=)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2656854T1 (sl) * 2003-02-04 2015-09-30 Cornell Research Foundation, Inc. Uporabe aromatsko-kationskega peptida
JP4879020B2 (ja) * 2003-05-01 2012-02-15 コーネル リサーチ ファウンデイション インコーポレイテッド 細胞に分子を送達する方法及び担体複合体
CA2851972C (en) * 2004-01-23 2015-06-23 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
AU2014203126B2 (en) * 2005-09-16 2016-03-10 Cornell Research Foundation, Inc. Methods for reducing cd36 expression
CA2947335A1 (en) * 2005-09-16 2007-03-29 Cornell Research Foundation, Inc. Methods for reducing cd36 expression
EP3103467A1 (en) 2008-02-07 2016-12-14 Cornell University Methods for preventing or treating insulin resistance
DK2262520T3 (en) * 2008-02-26 2017-08-07 Univ Cornell COMPOSITIONS FOR PREVENTION AND TREATMENT OF Kidney Injury
DE102008061044A1 (de) * 2008-12-11 2010-06-17 Henkel Ag & Co. Kgaa Zusammensetzung mit antioxidativ wirksamen Peptiden
EP3563862B1 (en) 2009-03-20 2021-05-05 The General Hospital Corporation d/b/a Massachusetts General Hospital D-arg-2'6'-dimethyltyrosine-lys-phe-nh2 for use in the prevention of secondary complications of burn injuries
CN105031605A (zh) * 2009-08-12 2015-11-11 康奈尔大学 预防或治疗代谢综合症的方法
PL2470191T3 (pl) 2009-08-24 2014-09-30 Stealth Peptides Int Inc Sposoby i kompozycje do profilaktyki lub leczenia stanów okulistycznych
EP2485749A4 (en) * 2009-10-05 2013-07-24 Univ Cornell METHOD FOR THE PREVENTION AND TREATMENT OF HEART FAILURE
EP3266462A1 (en) * 2009-12-31 2018-01-10 Stealth Peptides International, Inc. Methods for performing a coronary artery bypass graft procedure
CN103751763A (zh) * 2009-12-31 2014-04-30 康肽德生物医药技术有限公司 用于预防或治疗血管阻塞损伤的方法
AU2011207432A1 (en) * 2010-01-25 2012-08-02 Cornell University Aromatic-cationic peptides and uses of same
EP3332795A1 (en) * 2010-02-26 2018-06-13 Cornell University Cornell Center For Technology, Enterprise & Commercialization ("CCTEC") Mitochondrial-targeted antioxidants protect against mechanical ventilation-induced diaphragm dysfunction and skeletal muscle atrophy
EP3375449A1 (en) 2010-03-15 2018-09-19 Stealth Peptides International, Inc. Combination therapies using cyclosporine and aromatic cationic peptides
US20110245183A1 (en) * 2010-04-06 2011-10-06 Perricone Nicholas V Topical Uses of Szeto-Schiller Peptides
US20110245182A1 (en) * 2010-04-06 2011-10-06 Perricone Nicholas V Topical Uses of Szeto-Schiller Peptides
JP2013532124A (ja) * 2010-05-03 2013-08-15 ステルス ペプチドズ インターナショナル インコーポレイテッド 芳香族系陽イオンペプチド及びその使用
JP6319738B2 (ja) * 2010-07-09 2018-05-09 ステルス ペプチドズ インターナショナル インコーポレイテッド 虚血／再灌流障害に続くノーリフローの予防又は処置方法
WO2014137496A1 (en) * 2013-03-08 2014-09-12 The Administrators Of The Tulane Educational Fund Mu opioid receptor agonist analogs of the endomorphins
US20160176930A1 (en) 2010-07-09 2016-06-23 The Administrators Of The Tulane Educational Fund Mu opioid receptor agonist analogs of the endomorphins
US20120083452A1 (en) 2010-09-30 2012-04-05 Perricone Nicholas V Topical Anesthetic Uses of Szeto-Schiller Peptides
CA2831151A1 (en) * 2011-03-24 2012-09-27 Cornell University Aromatic-cationic peptides and uses of same
HK1200459A1 (en) 2011-09-19 2015-08-07 Gencia Corporation Modified creatine compounds
AU2012315586B2 (en) 2011-09-29 2017-07-20 Mayo Foundation For Medical Education And Research Aromatic-cationic peptides and methods for using same
WO2013059071A1 (en) * 2011-10-17 2013-04-25 Cornell University Aromatic-cationic peptides and uses of same
EP3009141A1 (en) * 2011-12-09 2016-04-20 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
JP6317324B2 (ja) 2012-03-30 2018-04-25 ステルス ペプチドズ インターナショナル インコーポレイテッド 神経障害を予防および処置するための方法および組成物
HK1210953A1 (en) * 2012-08-02 2016-05-13 Stealth Peptides International, Inc. Methods for treatment of atherosclerosis
AU2013334788A1 (en) * 2012-10-22 2015-06-04 Henry Ford Health Systems Methods for reducing risks associated with heart failure and factors associated therewith
CN110339339A (zh) 2013-03-01 2019-10-18 康德生物医疗技术公司 治疗线粒体疾病的方法
EP3626252A1 (en) 2013-03-01 2020-03-25 Stealth Biotherapeutics Corp Methods and compositions for the prevention or treatment of barth syndrome
EP2989120A4 (en) 2013-04-25 2017-04-19 Carmel-Haifa University Economic Corp. Synthetic anti-inflammatory peptides and use thereof
US10047395B2 (en) 2013-06-26 2018-08-14 Stealth Biotherapeutics Corp Methods and compositions for detecting and diagnosing diseases and conditions
CA2919992C (en) * 2013-08-01 2022-08-09 Stealth Biotherapeutics Corp Methods and compositions for preventing or treating leber's hereditary optic neuropathy
WO2015017861A1 (en) 2013-08-02 2015-02-05 Stealth Peptides International, Inc. Methods and compositions for the prevention and treatment of friedreich's ataxia
EP3052115A4 (en) * 2013-09-30 2017-09-27 Cornell University Cardiolipin-targeted peptides inhibit beta-amyloid oligomer toxicity
US11491480B2 (en) 2014-06-13 2022-11-08 Children's Medical Center Corporation Products and methods to isolate mitochondria
EP3160984B1 (en) 2014-06-25 2021-04-14 Flamma S.P.A. Process for preparing d-arginyl-2,6-dimethyl-l-tyrosyl-l-lysyl-l-phenylalaninamide
WO2016001042A1 (en) 2014-06-30 2016-01-07 Flamma S.P.A. Process for the production of d-arginyl-2,6-dimethyl-l-tyrosyl-l-lysyl-l-phenylalaninamide
WO2016004093A2 (en) * 2014-07-01 2016-01-07 Stealth Biotherapeutics Corp Therapeutic compositions including galectin-3 inhibitors and uses thereof
CN104306954B (zh) * 2014-09-25 2016-08-24 中山大学 Wry三肽在制备治疗阿尔茨海默症药物中的用途
EP3212194A4 (en) 2014-10-29 2018-06-20 University Of Maryland Methods of treating age-related symptoms in mammals and compositions therefor
WO2017015660A1 (en) * 2015-07-23 2017-01-26 Salk Institute For Biological Studies Prevention and treatment of aging and neurodegenerative diseases
CA3006698A1 (en) * 2015-11-30 2017-06-08 Peter Schiller Aromatic-cationic peptides conjugated to antioxidants and their use in treating complex regional pain syndrome
SI4272834T1 (sl) 2016-01-15 2026-03-31 Beth Israel Deaconess Medical Center, Inc. Terapevtska uporaba mitohondrijev in kombiniranih mitohondrijskih sredstev
CN115160402A (zh) * 2016-03-11 2022-10-11 隐形生物治疗公司 结晶盐形式
CA3020393A1 (en) 2016-04-11 2017-10-19 Carnot, Llc Chiral peptides
JP6427691B2 (ja) 2016-11-30 2018-11-21 株式会社ダイセル 撮像装置用レンズモジュール及びその製造方法
CN110914287A (zh) 2017-04-05 2020-03-24 隐形生物治疗公司 Boc-d-arg-dmt-lys-(boc)-phe-nh2的结晶盐形式
CN115109116A (zh) 2017-08-17 2022-09-27 凯瑞康宁生物工程（武汉）有限公司 活性氧清除剂衍生物的制备及用途
WO2019041361A1 (en) 2017-09-04 2019-03-07 Xw Laboratories, Inc. PREPARATION AND USE OF A REACTIVE OXYGEN SPECIES TRAPPER
JP6958860B2 (ja) * 2017-11-07 2021-11-02 学校法人自治医科大学 ミトコンドリアの機能障害の改善剤、及びミトコンドリアの機能障害に起因する疾患又は症状の予防又は治療薬、並びにそれらの用途
US10676506B2 (en) 2018-01-26 2020-06-09 Stealth Biotherapeutics Corp. Crystalline bis- and tris-hydrochloride salt of elamipretide
US12404300B2 (en) 2018-12-18 2025-09-02 Stealth Biotherapeutics Inc. Mitochondria-targeting peptides
EP3962365A4 (en) * 2019-05-02 2023-02-01 Children's Medical Center Corporation PROPHYLACTIC AND THERAPEUTIC USE OF MITOCHONDRIA AND COMBINED MITOCHONDRIA
EP3771467A1 (en) 2019-07-30 2021-02-03 Fundacio Institut de Recerca de l'Hospital de la Santa Creu i sant Pau Ss-31 for the prevention and/or treatment of aneurysm
CA3191819A1 (en) * 2020-09-09 2022-03-17 Hazel Szeto Methods and compositions for delivery of biotin to mitochondria
CN117881411A (zh) 2021-06-01 2024-04-12 艾迪雅生物有限责任公司 用于眼部药物的延长释放药物递送系统和使用方法

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5602100A (en) 1988-06-30 1997-02-11 Astra Ab Dermorphin analogs having pharmacological activity
EP0350221B1 (en) 1988-06-30 1996-04-17 Astra Aktiebolag Dermorphin analogs, their methods of preparation, pharmaceutical compositions, and methods of therapeutic treatment using the same
US5670617A (en) * 1989-12-21 1997-09-23 Biogen Inc Nucleic acid conjugates of tat-derived transport polypeptides
ES2117640T3 (es) * 1990-01-17 1998-08-16 Univ California Composicion para mejorar la supervivencia de materiales biologicos.
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
IS4261A (is) 1994-02-21 1995-08-22 Astra Aktiebolag Nýir peptíð-ópíóíðar til meðhöndlunar á verkjum og notkun þeirra
ATE255450T1 (de) * 1995-06-09 2003-12-15 Hisamitsu Pharmaceutical Co Matrix für iontophorese
US5849761A (en) * 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
EA001713B1 (ru) * 1996-10-07 2001-08-27 Эли Лилли Энд Компани Соединения, полезные для использования в качестве нейрозащитных средств
US5885958A (en) * 1997-03-25 1999-03-23 Administrators Of The Tulane Educational Fund Mu-opiate receptor peptides
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
CA2314267A1 (en) * 1997-12-10 1999-06-17 Washington University Anti-pathogen system and methods of use thereof
JP2002512954A (ja) * 1998-04-24 2002-05-08 マイトコー ミトコンドリア関連疾患を処置するための化合物および方法
US6472378B2 (en) * 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
GB9905503D0 (en) * 1999-03-10 1999-05-05 Adprotech Plc Novel compound formulations and methods of delivery
SE9900961D0 (sv) 1999-03-16 1999-03-16 Astra Ab Novel compounds
AU7855900A (en) * 1999-10-04 2001-05-10 University Of Medicine And Dentistry Of New Jersey Methods for identifying rna binding compounds
US6759520B1 (en) * 1999-10-28 2004-07-06 The New England Medical Center Hospitals, Inc. Chimeric analgesic peptides
US20050192215A1 (en) 2000-01-21 2005-09-01 Malabika Ghosh Methods and materials relating to novel polypeptides and polynucleotides
EP1303186B1 (en) * 2000-07-18 2011-01-26 Cornell Research Foundation, Inc. Medicinal uses of mu-opioid receptor agonists
US6900178B2 (en) * 2000-09-12 2005-05-31 University Of Kentucky Research Foundation Protection against ischemia and reperfusion injury
CA2430409A1 (en) * 2000-11-28 2002-06-06 Guilford Pharmaceuticals Inc. Bisubstituted carbocyclic cyclophilin binding compounds and their use
US6545097B2 (en) * 2000-12-12 2003-04-08 Scimed Life Systems, Inc. Drug delivery compositions and medical devices containing block copolymer
JP2004532187A (ja) * 2001-01-25 2004-10-21 ギルフォード ファーマシュウティカルズ インコーポレイテッド 三置換カルボサイクリックサイクロフィリン結合化合物とその用途
US20030077826A1 (en) * 2001-02-02 2003-04-24 Lena Edelman Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (PTPC)
AU2002247153A1 (en) * 2001-02-16 2002-09-04 Cordis Corporation Balloon catheter stent delivery system with ridges
WO2002074194A2 (en) * 2001-03-16 2002-09-26 Sts Biopolymers, Inc. Stent with medicated multi-layer hydrid polymer coating
JPWO2002102833A1 (ja) * 2001-06-15 2004-09-30 千寿製薬株式会社 新規エンドモルフィン誘導体
CN101440124B (zh) * 2003-02-04 2012-07-18 科内尔研究基金会 用于防止线粒体通透性改变的方法
SI2656854T1 (sl) * 2003-02-04 2015-09-30 Cornell Research Foundation, Inc. Uporabe aromatsko-kationskega peptida
JP4879020B2 (ja) 2003-05-01 2012-02-15 コーネル リサーチ ファウンデイション インコーポレイテッド 細胞に分子を送達する方法及び担体複合体
JP2005005762A (ja) * 2003-06-09 2005-01-06 Fujitsu Ltd 送信電力制御方法及び装置
US7232824B2 (en) 2003-09-30 2007-06-19 Scios, Inc. Quinazoline derivatives as medicaments
CA2851972C (en) 2004-01-23 2015-06-23 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
CA2947335A1 (en) 2005-09-16 2007-03-29 Cornell Research Foundation, Inc. Methods for reducing cd36 expression

Similar Documents

Publication Publication Date Title
JP2006516652A5 (https=)
CA2515080A1 (en) Methods for preventing mitochondrial permeability transition
RU2006130431A (ru) Способ уменьшения окислительного повреждения (варианты)
JP2007518818A5 (https=)
Schiller et al. Synthesis and in vitro opioid activity profiles of DALDA analogues
US6320024B1 (en) Method for design of substances that enhance memory and improve the quality of life
US9023986B2 (en) Glucose-dependent insulinotropic peptide analogs
JP2003503312A5 (https=)
WO2002026774A2 (en) Melanocortin receptor ligands
AU2001296313A1 (en) Melanocortin receptor ligands
IL191636A (en) Neurolipeptide-2 receptor agonists, medicinal preparations containing them and their use in the preparation of drugs
CN102574894A (zh) 稳定化的黑皮质素配体
RU2010111114A (ru) Нейропротективное действие с применением nap-подобных и sal-подобных пептидных миметиков
JPS59139347A (ja) Ｇｒｆ類似体
US9611297B1 (en) Compositions and methods for the treatment of cast nephropathy and related conditions
Yasuda-Kamatani et al. A novel D-amino acid-containing peptide, fulyal, coexists with fulicin gene-related peptides in Achatina atria
US8415292B2 (en) Compositions and methods for inhibiting the interaction between CFTR and CAL
JP2009519212A5 (https=)
CA2769013C (en) Motilin-like peptide compound having transmucosal absorbability imparted thereto
JP6795258B2 (ja) 医薬化合物
CN115298194A (zh) Vipr2拮抗肽
IE903958A1 (en) Reduced irreversible bombesin antagonists
Mukai et al. Structure-activity relationships of mammalian bombesin-like neuropeptides in the contraction of rat uterus
Mansfeld et al. Synthesis and plasma stability of disulfide-bridged cyclic endomorphin-1 derivatives
US20030032774A1 (en) Novel opioid peptides for the treatment of pain